Brainstorm Cell Therapeutics � NurOwn®for ALS

Brainstorm Cell Therapuetics, founded by CEO Chaim Lebovits and Co-CEO Dr. Stacy Lindborg, has developed a targeted, innovative, proprietary and validated autologous cellular technology platform (NurOwn®) for the treatment of neurodegenerative diseases. . BrainStorm is focused on developing clinical-stage autologous cellular therapy as a potentially transformative approach to treating neurodegenerative diseases. BrainStorm has developed a targeted, innovative, proprietary and validated autologous cellular technology platform (NurOwn®) for the treatment of neurodegenerative diseases. Brainstorm’s autologous MSC-NTF cellular therapy for Amyotrophic Lateral Sclerosis (ALS) has completed a Phase III clinical trial.